CA3243297A1 - FITUSIRAN USED TO IMPROVE OUTCOMES REPORTED BY HEMOPHILIA PATIENTS - Google Patents
FITUSIRAN USED TO IMPROVE OUTCOMES REPORTED BY HEMOPHILIA PATIENTSInfo
- Publication number
- CA3243297A1 CA3243297A1 CA3243297A CA3243297A CA3243297A1 CA 3243297 A1 CA3243297 A1 CA 3243297A1 CA 3243297 A CA3243297 A CA 3243297A CA 3243297 A CA3243297 A CA 3243297A CA 3243297 A1 CA3243297 A1 CA 3243297A1
- Authority
- CA
- Canada
- Prior art keywords
- fitusiran
- qol
- patient
- hemophilia
- questionnaire
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293070P | 2021-12-22 | 2021-12-22 | |
| US63/293,070 | 2021-12-22 | ||
| US202263305550P | 2022-02-01 | 2022-02-01 | |
| US63/305,550 | 2022-02-01 | ||
| US202263335535P | 2022-04-27 | 2022-04-27 | |
| US63/335,535 | 2022-04-27 | ||
| US202263359717P | 2022-07-08 | 2022-07-08 | |
| US63/359,717 | 2022-07-08 | ||
| US202263382223P | 2022-11-03 | 2022-11-03 | |
| US63/382,223 | 2022-11-03 | ||
| US202263386489P | 2022-12-07 | 2022-12-07 | |
| US63/386,489 | 2022-12-07 | ||
| PCT/US2022/082213 WO2023122713A1 (en) | 2021-12-22 | 2022-12-22 | Fitusiran for use in improving patient-reported outcome in hemophilia patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3243297A1 true CA3243297A1 (en) | 2023-06-29 |
Family
ID=85227438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3243297A Pending CA3243297A1 (en) | 2021-12-22 | 2022-12-22 | FITUSIRAN USED TO IMPROVE OUTCOMES REPORTED BY HEMOPHILIA PATIENTS |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250064842A1 (https=) |
| EP (1) | EP4452280A1 (https=) |
| JP (1) | JP2025500412A (https=) |
| KR (1) | KR20240138572A (https=) |
| AU (1) | AU2022419588A1 (https=) |
| CA (1) | CA3243297A1 (https=) |
| IL (1) | IL313677A (https=) |
| MX (1) | MX2024007894A (https=) |
| TW (1) | TW202342065A (https=) |
| WO (1) | WO2023122713A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025171279A1 (en) * | 2024-02-09 | 2025-08-14 | Genzyme Corporation | Treatment of hemophilia with fitusiran |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| KR20180095843A (ko) | 2015-12-07 | 2018-08-28 | 젠자임 코포레이션 | Serpinc1-연관 장애의 치료를 위한 방법 및 조성물 |
| TW202434265A (zh) | 2017-07-10 | 2024-09-01 | 美商健贊公司 | 於患有血友病之個體中治療出血事件之方法及組成物 |
| WO2022120291A1 (en) * | 2020-12-06 | 2022-06-09 | Genzyme Corporation | Treatment of hemophilia with fitusiran |
-
2022
- 2022-12-21 TW TW111149131A patent/TW202342065A/zh unknown
- 2022-12-22 KR KR1020247024462A patent/KR20240138572A/ko active Pending
- 2022-12-22 EP EP22857063.6A patent/EP4452280A1/en active Pending
- 2022-12-22 AU AU2022419588A patent/AU2022419588A1/en active Pending
- 2022-12-22 MX MX2024007894A patent/MX2024007894A/es unknown
- 2022-12-22 CA CA3243297A patent/CA3243297A1/en active Pending
- 2022-12-22 US US18/723,352 patent/US20250064842A1/en active Pending
- 2022-12-22 WO PCT/US2022/082213 patent/WO2023122713A1/en not_active Ceased
- 2022-12-22 JP JP2024537896A patent/JP2025500412A/ja active Pending
- 2022-12-22 IL IL313677A patent/IL313677A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202342065A (zh) | 2023-11-01 |
| JP2025500412A (ja) | 2025-01-09 |
| AU2022419588A1 (en) | 2024-08-01 |
| MX2024007894A (es) | 2024-08-20 |
| US20250064842A1 (en) | 2025-02-27 |
| EP4452280A1 (en) | 2024-10-30 |
| WO2023122713A1 (en) | 2023-06-29 |
| KR20240138572A (ko) | 2024-09-20 |
| IL313677A (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260014188A1 (en) | Methods and compositions for treating hemophilia | |
| Bussel et al. | IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life | |
| US20240000744A1 (en) | Treatment of Hemophilia with Fitusiran | |
| WO2022120291A1 (en) | Treatment of hemophilia with fitusiran | |
| US20240417739A1 (en) | Compositions and methods for treatment of bleeding disorders | |
| JP2023552554A (ja) | フィツシランを用いた血友病の処置 | |
| US20250064842A1 (en) | Fitusiran for Use in Improving Patient-Reported Outcome in Hemophilia Patients | |
| WO2025059635A1 (en) | Treatment of hemophilia a with fitusiran | |
| CA3258425A1 (en) | TREATMENT OF HEMOPHILIA WITH FITUSIRAN IN PEDIATRIC PATIENTS | |
| CN118434425A (zh) | 用于改善血友病患者的患者报告结局的非妥西兰 | |
| WO2025171279A9 (en) | Treatment of hemophilia with fitusiran | |
| Aledort | Some aspects on the management of hemophilia | |
| TW202400657A (zh) | 治療a型血友病的方法 | |
| CN109627218A (zh) | 一种抗凝小分子化合物及其应用和包含其的药物 | |
| Pipe et al. | 5 HEMOSTATIC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240815 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240815 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240819 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240819 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251222 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251222 |